Last year, Edwards Lifesciences Corp generated 4.49B USD for its biggest-performing segment, Transcatheter Aortic Valve Replacement. The United States made the largest contribution, accounting for 3.54B USD last year. For the latest quarter, Edwards Lifesciences Corp reported the revenue of 1.26B USD for the period ending 2026-06-30, which came from the top-performing segment, Transcatheter Aortic Valve Replacement. United States contributed the highest revenue, at 1.00B USD.